VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma

M. Pineda-Roman, M. Zangari, F. van Rhee, E. Anaissie, J. Szymonifka, A. Hoering, N. Petty, J. Crowley, J. Shaughnessy, J. Epstein, B. Barlogie

Research output: Contribution to journalArticlepeer-review

123 Scopus citations

Fingerprint

Dive into the research topics of 'VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma'. Together they form a unique fingerprint.

Medicine & Life Sciences